Eribulin Combined With Anlotinib in Metastatic HER2 Negative Breast Cancer

NCT04624711 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

40

Enrollment

OTHER

Sponsor class

Conditions

HER2-negative Breast Cancer

Interventions

DRUG: Eribulin Mesylate
DRUG: Anlotinib hydrochloride

Sponsor

The First Affiliated Hospital with Nanjing Medical University